[1]郭小艳,于桂萍.抗幽门螺杆菌疗法联合新辅助化疗对胃癌术后疗效及患者血清VEGF、bFGF的影响[J].陕西医学杂志,2019,(8):1010-1012，1031.
　GUO Xiaoyan,YU Guiping..Effect of anti-Helicobacter pylori therapy combined with neoadjuvant chemotherapy on serum VEGF and bFGF in postoperative patients with gastric cancer[J].,2019,(8):1010-1012，1031.
点击复制

抗幽门螺杆菌疗法联合新辅助化疗对胃癌术后疗效及患者血清VEGF、bFGF的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年8期
页码:
1010-1012，1031
栏目:
临床研究
出版日期:
2019-08-05

文章信息/Info

Title:
Effect of anti-Helicobacter pylori therapy combined with neoadjuvant chemotherapy on serum VEGF and bFGF in postoperative patients with gastric cancer
文章编号:
DOI:10.3969/j.issn.1000-7377.2019.08.014
作者:
郭小艳; 于桂萍
西安市第九医院（西安710054）
Author(s):
GUO Xiaoyan;  YU Guiping.
Ninth Hospital of Xi’an (Xi’an 710054)
关键词:
胃癌; 抗幽门螺杆菌疗法; 化疗; 血管内皮生长因子; 成纤维细胞生长因子; 生存期
Keywords:
Key words Gastric cancer; Anti-Helicobacter pylori therapy; Chemotherapy; Vascular endothelial growth factor;  Fibroblast growth factor;  Survival
分类号:
R735.2
文献标志码:
A
摘要:
摘 要 目的：研究抗幽门螺杆菌（HP）疗法联合FOLFOX4化疗对胃癌术后患者血清血管内皮生长因子（VEGF）、成纤维细胞生长因子（bFGF）影响及治疗疗效。方法：收集胃癌根治术后患者80例，入组前均进行碳14呼气试验，均为HP阳性患者，随机数字分组法分为试验组和对照组，每组各40例。对照组仅进行FOLFOX4化疗，每2周1次，维持8～12次；试验组在上述基础上加用抗幽门螺杆菌治疗。比较两组间及治疗前后各时段血清VEGF、bFGF水平变化。对比两组无进展生存期（PFS）、总生存期（OS）及治疗期间不良反应情况。结果：两组患者治疗1个月、3个月、6个月、12个月时血清VEGF、bFGF值均呈明显下降趋势，且试验组治疗1个月、3个月、6个月、12个月时血清VEGF、bFGF值均较对照组数值下降更明显（P＜0.05）。试验组PFS及OS明显长于对照组（P＜0.05）。治疗期间试验组Ⅰ~Ⅱ级恶心呕吐及感觉神经病变发生例数显著多于对照组（P<0.05）。结论：抗HP联合FOLFOX4化疗有效延长患者PFS和OS，安全性高，可有效提高患者生存质量。这可能与其能抑制肿瘤局部新生血管生成，抑制肿瘤细胞局部复发和转移等机制有关。
Abstract:
Abstract Objective:To study the effect of anti-Helicobacter pylori (HP) therapy combined with FOLFOX4 chemotherapy on serum vascular endothelial growth factor (VEGF) and fibroblast growth factor (bFGF) in patients with gastric cancer after operation and its therapeutic effect.Method:80 patients with radical gastrectomy were enrolled. All patients underwent carbon 14 breath test before the enrollment, all were infected with HP. All patients were divided into experimental group and control group by the randomized digital grouping method, with 40 cases in each group.In the control group, only FOLFOX4 chemotherapy was performed, once every 2 weeks, and maintained 8 to 12 times; the experimental group was treated with anti-Helicobacter pylori on the above basis. The levels of serum VEGF and bFGF were compared between the two groups and before and after treatment.The progression-free survival (PFS), overall survival (OS), and adverse events during treatment were compared between the two groups.Results: During the treatment period, serum VEGF and bFGF levels of two groups decreased significantly at 1 month, 3 months, 6 months, and 12 months, and the serum VEGF and bFGF levels in the experimental group were significantly lower than those in the control group at 1 month, 3 months, 6 months and 12 months (P<0.05).PFS and OS in the experimental group were significantly longer than the control group (P<0.05). During the treatment period, the number of cases of grade I~II nausea and vomiting and sensory neuropathy in the experimental group was significantly higher than that in the control group (P<0.05).Conclusion:Anti-Hp combined with FOLFOX4 chemotherapy can effectively prolong PFS and OS, and it is safe and can improve the quality of life of patients. This may be related to its ability to inhibit local neovascularization of tumors, inhibit local recurrence and metastasis of tumor cells.

参考文献/References:

[1] Bagheri V, Memar B, Momtazi AA , et al. Cytokine networks and their association with Helicobacter pylorir, infection in gastric carcinoma[J]. Journal of Cellular Physiology, 2017, 233(4):2791-2803.
[2] Kim HJ, Hwang SW, Kim N, et al. Helicobacter pylori and molecular markers as prognostic indicators for gastric cancer in korea[J]. Journal of Cancer Prevention, 2014, 19(1):56-67.
[3] 熊红兵, 吴兴明, 肖 然,等. 胃癌和胃幽门螺旋杆菌的相关性研究分析[J]. 中国医药科学, 2017, 7(17):227-229,236.
[4] Liu N , Liu X , Zhou N , et al. Gene expression profiling and bioinformatics analysis of gastric carcinoma[J]. Experimental and Molecular Pathology, 2014, 96(3):361-366.
[5] 余 明, 王 博, 张亚飞,等. 癌前病变及胃癌与幽门螺杆菌感染的关系探讨[J]. 陕西医学杂志, 2018, 47(11):1424-1426.
[6] 蔡靓羽, 尹卫娟, 徐敏逸. 分泌蛋白DKK1（Dickkopf-1）在胃癌患者血清及组织中的表达及其意义[J]. 中国现代医学杂志, 2014, 24(6):1-8.
[7] Zhang X, Peng J.VEGF promotes gastric cancer development by upregulating CRMP4[J]. Oncotarget, 2016, 7(13):17074-17086. 
[8] Mingming H, Ying H, Jiabei H, et al. Prognostic value of basic fibroblast frowth factor (bFGF) in lung cancer: a systematic review with meta-analysis[J]. PLos oen, 2016, 11(1): 147374-147386. 
[9] 陈晓兵. 胃癌患者幽门螺杆菌感染情况与肿瘤恶性程度的相关性研究[J]. 海南医学院学报, 2017, 23(4): 475-477.
[10] 石远凯, 孙 艳. 临床肿瘤内科手册[M].6版.北京:人民卫生出版社, 2015:379-380. 
[11] 杨晓晔. 奥沙利铂联合S-1新辅助化疗对进展期胃癌肿瘤切除率和生存率的影响[J]. 河北医药, 2016, 38(3):399-400．
[12] 高 文, 胡伏莲, 成 虹,等. 国产药物组成的四联疗法对胃炎及十二指肠溃疡患者幽门螺杆菌感染根除效果的前瞻性多中心随机对照研究[J]. 中华医学杂志, 2016, 96(4):260-264.

相似文献/References:

[1]侯洁心 ,郭萍△.免疫组化标志物Her2和肿瘤标志物在胃癌诊断中的价值分析*[J].陕西医学杂志,2019,(1):121.
　HOU Jiexin,GUO Ping..The value of immunohistochemical marker Her2 andtumor markers in the diagnosis of gastric cancer[J].,2019,(8):121.
[2]唐亚荣.循环热灌注化疗联合替吉奥及热疗治疗老年胃癌癌性腹水临床研究*[J].陕西医学杂志,2019,(4):435.
　TANG Yarong..Clinical effect analysis of combined therapy with tiago and hyperthermia in the treatment of malignant ascites in elderly patients with gastric cancer[J].,2019,(8):435.
[3]刘国庆,闫 龙△,高 任.1.5T磁共振扩散加权成像在胃癌淋巴结转移诊断中的应用价值*[J].陕西医学杂志,2019,(4):456.
　LIU Guoqing,YAN Long,GAO Ren..1.5T magnetic resonance diffusion weighted imaging in the diagnosis of lymph node metastasis of gastric cancer[J].,2019,(8):456.
[4]胡乃军,王海龙.胃腺癌组织中MMP11、MMP12和VEGFD的表达及临床意义[J].陕西医学杂志,2019,(5):554.
[5]米志宽,赵菊梅.抑癌基因甲基化与胃癌关系研究进展*[J].陕西医学杂志,2019,(5):679.
　MI Zhikuan,ZHAO Jumei..Research progress of relationships between tumor suppressor gene methylation and gastric cancer[J].,2019,(8):679.
[6]石颖鹏,王敏娟,李程亮.肠化生相关分子与胃癌的发生和进展研究概况[J].陕西医学杂志,2019,(7):958.
　SHI Yingpeng,WANG Minjuan,LI Chengliang,et al.Intestinal metaplasia-related molecules and the occurrence and progress of gastric cancer[J].,2019,(8):958.
[7]柯东平,毛俊倩,郭甲民,等.SCNN1B与胃癌细胞上皮间质转化相关性实验研究*[J].陕西医学杂志,2019,(9):1115.
　KE Dongping,MAO Junqian,GUO Jiamin,et al.Research on the correlation between SCNN1B and〖JZ〗 epithelialmesenchymal transformation in gastric cancer cells[J].,2019,(8):1115.
[8]王小林,马任远,张 哲.腹腔镜手术治疗老年进展期胃癌50例临床疗效分析[J].陕西医学杂志,2019,(10):1360.
[9]刘维帅,郭晓宁,杨 洋,等.胃癌病理类型及临床预后与血清miR-133a和DKK-1相关性分析[J].陕西医学杂志,2020,49(6):751.[doi:DOI:10.3969/j.issn.10007377.2020.06.028]
　LIU Weishuai,GUO Xiaoning,YANG Yang,et al.Correlation of pathological types and clinical prognosis of gastric cancer with serum miR-133a and DKK-1[J].,2020,49(8):751.[doi:DOI:10.3969/j.issn.10007377.2020.06.028]
[10]张 铭,张新望,艾 静,等.胃癌患者血浆微小RNA-100表达水平及其临床意义*[J].陕西医学杂志,2020,49(7):893.[doi:DOI:10.3969/j.issn.10007377.2020.07.034]
　ZHANG Ming,ZHANG Xinwang,AI Jing,et al.Study on expression level of microRNA-100 in plasma of patients with gastric cancer[J].,2020,49(8):893.[doi:DOI:10.3969/j.issn.10007377.2020.07.034]

更新日期/Last Update: 2019-08-13